IP Library › Granted Patent US 7,147,864
Granted Patent B2
US 7,147,864 · App. 10/806,494 · Granted Dec 12, 2006

Methods for preventing photodamaged skin by administering selegiline or desmethylselegiline

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,147,864
App. No.
10/806,494
Granted
Dec 12, 2006
Kind
B2
Abstract

The present invention is directed to methods that can be used in the treatment of wounds, burns, and photodamaged skin. Methods can be used for both humans and animals and involve the administration of compositions containing selegiline and/or desmethylselegiline.

Claims (23)

1. A method of preventing or reducing photodamage to skin cells of a subject comprising administering a composition comprising selegiline and/or desmethylselegiline to the subject in an amount effective to reduce apoptosis of skin cells exposed to electromagnetic or ionizing radiation.

2. The method of claim 1 , wherein the composition is a topical composition.

3. The method of claim 2 , wherein the topical composition is in a form selected from the group consisting of a cream, gel, transdermal patch, salve, lotion, and spray.

4. The method of claim 2 , wherein the topical composition comprises selegiline at a concentration of between 1×10 −11 moles/liter and 1×10 −11 moles/liter.

5. The method of claim 2 , wherein the topical composition comprises desmethylselegiline at a concentration of between 1×10 −11 moles/liter and 1×10 −3 moles/liter.

6. The method of claim 1 , wherein the composition comprises desmethylselegiline in the form of its R(−) enantiomer and the S(+) enantiomer is substantially absent.

7. The method of claim 1 , wherein the composition comprises desmethylselegiline in the form of its S(+)enantiomer and the R(−) enantiomer is substantially absent.

8. The method of claim 1 , wherein the composition further comprises a diluent or carrier comprising one or more compounds selected from the group consisting of water, suspending agents, thickeners, humectants, preservatives, emollients, emulsifiers, and film formers.

9. The method of claim 1 , wherein the selegiline is administered as the free base.

10. The method of claim 1 , wherein the selegiline is administered as a pharmaceutically acceptable acid addition salt.

11. The method of claim 1 , wherein the desmethylselegiline is administered as the free base.

12. The method of claim 1 , wherein the desmethylselegiline is administered as a pharmaceutically acceptable acid addition salt.

13. A method of treating a subject for photodamaged skin, wherein the photodamage results from exposure to electromagnetic or ionizing radiation, comprising administering a topical composition comprising selegiline and/or desmethylselegiline to the skin of the subject in an amount effective to reduce oxidative damage resulting from exposure to electromagnetic or ionizing radiation.

14. The method of claim 13 , wherein the topical composition is in a form selected from the group consisting of a cream, gel, transdermal patch, salve, lotion, and spray.

15. The method of claim 13 , wherein the topical composition comprises selegiline at a concentration of between 1×10 −11 moles/liter and 1×10 −3 moles/liter.

16. The method of claim 13 , wherein the topical composition comprises desmethylselegiline at a concentration of between 1×10 −11 moles/liter and 1×10 −3 moles/liter.

17. The method of claim 13 , wherein the topical composition comprises desmethylselegiline in the form of its R(−) enantiomer and the S(+) enantiomer is substantially absent.

18. The method of claim 13 , wherein the topical composition comprises desmethylselegiline in the form of its S(+)enantiomer and the R(−) enantiomer is substantially absent.

19. The method of claim 15 , wherein the topical composition further comprises a diluent or carrier comprising one or more compounds selected from the group consisting of water, suspending agents, thickeners, humectants, preservatives, emollients, emulsifiers, and film formers.

20. The method of claim 15 , wherein the selegiline is administered as the free base.

21. The method of claim 15 , wherein the selegiline is administered as a pharmaceutically acceptable acid addition salt.

22. The method of claim 15 , wherein the desmethylselegiline is administered as the free base.

23. The method of claim 15 , wherein the desmethylselegiline is administered as a pharmaceutically acceptable acid addition salt.